Morbidity-mortality at 30 days of Nissen sleeve: a french national multicenter study

Pr Claire Blanchard-CHU Nantes






Conflicts of interest

None

Sleeve gastrectomy and reflux

TABLE 2. Summary of All Study Outcomes (P < 0.0001 for All Studies)

Outcome	All Studies	Long Term (≥24 mo)
Overall increase in reported reflux	19%	19%
De novo reflux	23%	20%
Esophagitis found	30%	28%
Barrett's esophagus	6%	8%
Postoperative hiatus hemia rate	41%	-
PPI use (postoperative)	38%	36%
Revision to RYGB for severe reflux	4%	4%
BMI change	-13.29 kg/m^2	-12.56 kg/m^2
EWL	62%	61%
Diabetic resolution	66%	66%
GERD 2018 Lyon Consensus criteria (borderline)	37%	4114
GERD 2018 Lyon Consensus criteria (conclusive)	8%	-




Contraindications to gastric bypass surgery

- Multi-operated patient in supra mesocolic
- Complex eventration
- Malabsorption of treatments
- Biermer's disease
- At the time of the assessment, esophagitis grade C, D, EBO
- Osteoporosis?


INNOVATIONS: NISSEN- SLEEVE















Surgery for Obesity and Related Diseases 12 (2016) 1832-1837

SURGERY FOR OBESITY AND RELATED DISEASES

Original article

Nissen Sleeve (N-Sleeve) operation: preliminary results of a pilot study David Nocca, M.D., Ph.D. a,b, El Mehdi Skalli, M.D. Eric Boulay, M.D. Marius Nedelcu, M.D. Jean Michel Fabre, M.D., Ph.D. A,b, Marcelo Loureiro, M.D., Ph.D. a,b,c,a

"CHU de Montpellier, Montpellier, France

Diversity Montpellier 1, Montpellier, France
Universidade Positivo, Curitiba, Brazil
Received December 29, 2015; accepted February 14, 2016

Material and methods

- Observational and multicenter cohort
- Study population: Patients operated on for nissen-SG in 2022 and 2023 (inclusion period) in the centers participating in the study and agreeing to participate in the study.
- Expert center with surgeons trained in the surgical technique

Protocol declared and validated by the GNEDS (Groupe Nantais Ethique dans le domaine de la santé) AVIS 22-01-281

Material and methods

Inclusion criteria:

- Patient between the ages of 18 and 65 years
- Patient able to attend all scheduled visits
- Patient affiliated to the French social security system
- Patient eligible for sleeve gastrectomy after multidisciplinary evaluation according to HAS 2009 criteria (BMI ≥ 40 kgs/m2 and/or BMI ≥ 35 kgs/m2 with comorbidities)

Non-inclusion criteria:

- Barrett's esophagus and stage III and IV esophagitis
- Pregnancy in progress
- Previous bariatric surgery
- History of reflux surgery- BMI>50kg/m²
- No affiliation to the French social security system
- Minor protected by law
- Deprivation of liberty by judicial or administrative decision
- Participation in another clinical research program

Objectives

Primary Objective:

- To study the postoperative morbidity at 30 days postoperatively of nissen sleeve gastrectomy

Primary endpoint:

Collection of complications at 30 days postoperatively (aphagia, gastric perforation, fistula...) with the classification according to Dindo-Clavien

Secondary objectives:

- 1- To study the presence and evolution (improvement or not) of clinical GERD postoperatively of nissen sleeve gastrectomy at 1 month, 6 months and 1 year
- 2- To study the postoperative morbidity of nissen sleeve gastrectomy at 6 months and one year postoperatively
- 3- To compare the 30-day postoperative morbidity of nissen sleeve gastrectomy with sleeve gastrectomy

Results

- 138 patients with 122 women (88.4%) were included in the study
- Mean age: 39.1 ± 11.0 years
- Mean BMI was $41.6 \pm 4.1 \text{ kg/m}^2$
- The comorbidities were :

17 (12.31%) diabetic patients including 3 on insulin (17.6%)

29 hypertensive patients (21%)

58 patients with sleep apnea (42%)

65 patients with reflux (47.1%) including 58 on PPI (42%)

Preoperatively: 27 patients (19.5%) had esophagitis and 29 patients (21%) hiatal hernia

Results

Intraoperatively: 135 N-Sleeves were performed (one intraoperative resection of the fundoplicature for vascularization defect, one large left liver and one presence of a diverticulum at the level of the greater curvature)

The operating time was 90.3 ± 35.1 min

The length of stay was 2.2 ± 1.3 days

The reintervention rate was 5.8 %

According to Clavien and Dindo, there were

- 3 Grade 1 complications: 2 ischemia of the spleen and hematoma liver
- 9 Grade 3-4 complications: 1 fistula with 1 twist under fundoplicature, 1 staple line bleeding, 2 endoscopy valve dilatations
- 5 complications with gastric perforation (3.62 %)

All the complication rate were 8.7%. Grade 3-4:6.5 % Mortality was 0%.

At one month postoperative, the BMI was $37.9 \pm 6.0 \text{ kg/m}^2$. None patient had reflux and 9 patients had dysphagia (6,5%)

Results of 2 literature reviews

487 PATIENTS
- 9.4% of complications
(3.1% gastric perforation)




Figure 1. Distribution of identified complications.

Carandina et al. Medicina 2021

Results of 2 literature reviews

Results

Six studies (485 patients) met the inclusion criteria. The age of the patient population ranged from 17 to 72 years old and 82% were females. All patients underwent sleeve-fundoplication. Rossetti, Collis-Nissen, and Nissen were the most commonly performed fundoplications. The estimated pooled prevalence of postoperative leak, gastric perforation, and overall complications were 1.0% (95% CI = 0.0–2.0%), 2.9% (95% CI = 0.0–8.3%), and 9.8% (95% CI = 6.7–13.4%), respectively. The pooled reoperation rate was 4.1% (95% CI = 1.3–10%). There was no mortality. At 12-month follow-up, the estimated pooled BMI and %EWL were 29.9 kg/m² (95% CI = 28.5–31.2) and 66.2% (95% CI = 59.3–71.1), respectively, while esophagitis, PPI consumption, and GERD rates were 8.0% (95% CI 3–21%), 7.8% (95% CI 5–13%), and 11% (95% CI 4–26%).

_ . .

Conclusion



- The results show a complication rate of 8.7% without mortality
- A learning curve is necessary to decrease the complication rate
- In view of the morbidity, this procedure should be reserved for the moment to expert centers. The long-term results, in particular on reflux and weight loss, are in progress

- Samuel Frey1, Marie de Montrichard1, Adel Abou mrad2, Laurent Arnalsteen3, Thibaut Coste4, Litavan Khamphommala5, Jean-Charles Vignal6, Geraud Tuyeras7, Fabien Stenard8, Thomas Gautier9, Maucour Christophe10 Blanchard Claire1
- 1. Chirurgie cancérologique, digestive et endocrinienne. Centre hospitalier universitaire de Nantes, Nantes, France.
- 2. CHR ORLEANS, France
- 3. Hôpital la Louvière à LILLE, France
- 4. Polyclinique Ste Thérèse à SETE, France
- 5. Clinique St Grégoire à RENNES, France
- 6. Clinique Chirurgicale du Libournais à LIBOURNE, France
- 7. CHU Toulouse, France
- 8. Clinique des Cèdres Echirolles, Grenoble, France
- 9. Clinique St Jean à MONTPELLIER, France
- 10. Clinique st André lambres les douai, France

